Rothschild & Co Asset Management US’s Phathom Pharmaceuticals PHAT Stock Holding History

Rothschild & Co Asset Management US’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.76M	Buy	245,658 +38,230	+18%	+$394K	0.04%	215
2022 Q3	$2.3M	Buy	207,428 +7,005	+3%	+$66.7K	0.04%	223
2022 Q2	$1.69M	Sell	200,423 -6,184	-3%	-$63.6K	0.03%	239
2022 Q1	$2.81M	Sell	206,607 -37,832	-15%	-$611K	0.04%	230
2021 Q4	$4.81M	Buy	244,439 +72,933	+43%	+$1.72M	0.06%	219
2021 Q3	$5.5M	Buy	171,506 +130	+0.1%	+$4.32K	0.07%	211
2021 Q2	$5.8M	Buy	+171,376	New	+$6.14M	0.07%	214

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Rothschild & Co Asset Management US's PHAT Position: Q4 2022 in Review

Rothschild & Co Asset Management US increased its Phathom Pharmaceuticals (PHAT) stake by 18% in Q4 2022, buying an estimated $394K and bringing the position to 245,658 shares worth $2.76M. The position accounts for 0.04% of the portfolio, ranked #215.

Rothschild & Co Asset Management US first reported a position in PHAT in Q2 2021 and has held it in 7 quarters since. The position peaked at $5.8M in Q2 2021. 87 funds tracked by Wall St. Rank hold PHAT as of Q4 2022.

Rothschild & Co Asset Management US held 245,658 shares of Phathom Pharmaceuticals worth $2.76M as of Q4 2022.
Rothschild & Co Asset Management US bought 38,230 Phathom Pharmaceuticals shares in Q4 2022, an estimated $394K.
Phathom Pharmaceuticals made up 0.04% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #215 holding.
Rothschild & Co Asset Management US first reported a position in Phathom Pharmaceuticals in Q2 2021 and has held it in 7 quarters since.
Rothschild & Co Asset Management US's Phathom Pharmaceuticals position peaked at $5.8M in Q2 2021.
87 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.